Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers

Ovarian cancer represents the most lethal tumor type among malignancies of the female reproductive system. Overall survival rates remain low. In this study, we identify the serine protease inhibitor Kazal type 1 (SPINK1) as a potential therapeutic target for a subset of ovarian cancers. We show that...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehner, Christine, Oberg, Ann L., Kalli, Kimberly R., Nassar, Aziza, Hockla, Alexandra, Pendlebury, Devon, Cichon, Magdalena A., Goergen, Krista M., Maurer, Matthew J., Goode, Ellen L., Keeney, Gary L., Jatoi, Aminah, Sahin-Tóth, Miklós, Copland, John A., Radisky, Derek C., Radisky, Evette S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742138/
https://www.ncbi.nlm.nih.gov/pubmed/26437224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742138/
https://www.ncbi.nlm.nih.gov/pubmed/26437224

Ejemplares similares